These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 3552537)

  • 1. Lack of effect of gliclazide on early diabetic nephropathy and retinopathy: a two-year controlled study.
    Jerums G; Murray RM; Seeman E; Cooper ME; Edgley S; Marwick K; Larkins RG; Martin TJ
    Diabetes Res Clin Pract; 1987; 3(2):71-80. PubMed ID: 3552537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of effect of gliclazide on platelet aggregation in insulin-treated and non-insulin-treated diabetes: a two-year controlled study.
    Larkins RG; Jerums G; Taft JL; Godfrey H; Smith IL; Martin TJ
    Diabetes Res Clin Pract; 1988 Jan; 4(2):81-7. PubMed ID: 3125029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes.
    Baba S; Nakagawa S; Takebe K; Goto Y; Maezawa H; Takeda R; Sakamoto N; Fukui I
    Tohoku J Exp Med; 1983 Dec; 141 Suppl():693-706. PubMed ID: 6440313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventive and therapeutic effects of gliclazide on diabetic retinopathy: comparison with glibenclamide treatment.
    Minami N; Ikeda Y; Abe M
    Tohoku J Exp Med; 1983 Dec; 141 Suppl():707-11. PubMed ID: 6440314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diabetic retinopathy. Effects of gliclazide].
    Lesobre B
    Journ Annu Diabetol Hotel Dieu; 1983; ():275-80. PubMed ID: 6358618
    [No Abstract]   [Full Text] [Related]  

  • 6. [Hypoglycemic and microvascular properties of gliclazide: a review of the latest international studies].
    Lesobre B
    Sem Hop; 1983 Jun; 59(24):1827-33. PubMed ID: 6308816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of glycaemic control, metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients.
    Collier A; Watson HH; Patrick AW; Ludlam CA; Clarke BF
    Diabete Metab; 1989; 15(6):420-5. PubMed ID: 2534084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term comparison of oral hypoglycemic agents in diabetic retinopathy. Gliclazide vs. other sulfonylureas.
    Akanuma Y; Kosaka K; Kanazawa Y; Kasuga M; Fukuda M; Aoki S
    Diabetes Res Clin Pract; 1988 Jul; 5(2):81-90. PubMed ID: 3416710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of glimepiride (HOE490) in NIDDM, including a double blind comparative study versus gliclazide.
    Tsumura K
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S147-9. PubMed ID: 8529507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of prolonged gliclazide therapy in non-insulin dependent diabetic subjects.
    Donatelli M; Sinagra D; Russo V; Bucalo ML; Giardina E; Cerasola GA; Bompiani G
    Pharmatherapeutica; 1985; 4(2):69-75. PubMed ID: 3903780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Value of gliclazide in the treatment of early diabetic retinopathy].
    Cabral BV; Fernando R; Villegas-Cinco A; Icasas-Cabral E; Cinco L
    Therapie; 1985; 40(4):231-3. PubMed ID: 4024018
    [No Abstract]   [Full Text] [Related]  

  • 12. The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy.
    Saberi M; Ramazani Z; Rashidi H; Saberi A
    Vasc Health Risk Manag; 2020; 16():241-248. PubMed ID: 32606720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of diabetic control in type 2 (non-insulin dependent) diabetic patients treated with different sulphonylureas.
    Harrower AD
    Curr Med Res Opin; 1985; 9(10):676-80. PubMed ID: 3935376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus.
    Holmes B; Heel RC; Brogden RN; Speight TM; Avery GS
    Drugs; 1984 Apr; 27(4):301-27. PubMed ID: 6373223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A new therapeutic approach to diabetes. Long-term survey].
    Charbonnel B
    Sem Hop Ther; 1977 Nov; 53(9):460-5. PubMed ID: 341321
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas.
    Harrower AD
    J Diabetes Complications; 1994; 8(4):201-3. PubMed ID: 7833494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary sulfonylurea failure: comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide.
    Satoh J; Takahashi K; Takizawa Y; Ishihara H; Hirai M; Katagiri H; Hinokio Y; Suzuki S; Tsuji I; Oka Y
    Diabetes Res Clin Pract; 2005 Dec; 70(3):291-7. PubMed ID: 15949862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Workshop VIII--Retinopathy, nephropathy, neuropathy, and tight control.
    Lebovitz HE; Vinik AI
    Am J Med; 1991 Feb; 90(2A):80S-84S. PubMed ID: 1994725
    [No Abstract]   [Full Text] [Related]  

  • 19. [The effects of prolonged treatment with gliclazide on the course of proteinuria and renal function in diabetic nephropathy].
    Lagrue G; Kazandjian M; Gumpelson A; Riveline B
    Therapie; 1978; 33(5):629-37. PubMed ID: 741422
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effects of gliclazide and glibenclamide on platelet function, fibrinolysis and metabolic control in diabetic patients with retinopathy (author's transl)].
    Chan TK; Chan V; Teng CS; Yeung RT
    Sem Hop; 1982 May; 58(19):1197-200. PubMed ID: 6285503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.